INTRODUCTION
For many years, there has been continued interest by Federal legislators and policymakers concerning health care for the four major Medicaid eligibility groups: aged, disabled (including blind), children, and adults. In the late 1980s, Congress expanded Medicaid coverage to several of these poverty-related groups. Eligibility expansions for older poverty-related children continued through the 1990s. The BBA of 1997 established the SCHIP to provide health insurance coverage for additional groups of children and adults with incomes above the income limits for Medicaid. The Ticket to Work and Work Incentives Improvement Act of 1999 expanded Medicare and Medicaid for some disabled beneficiaries who return to work. There also has been continued concern about the adequacy of Medicare coverage for disabled and aged enrollees. This concern has led to the enactment of legislation for a Federal Medicare prescription drug benefit and a protracted debate about the cost and financing of such a benefit. These interests must be viewed in the context of continued increases in health care spending for Medicaid recipients at a time when fiscal constraint for State budgets has become paramount.
Medicaid payments have now become a significant proportion of every State's budget. In FY 2000, Medicaid was the largest program to provide health care to poor and near poor Americans, covering over 44 million individuals. In that year, Medicaid spent nearly $206 billion, including $21 billion on outpatient drugs-$16.6 billion under FFS programs and an estimated $4.4 billion in prepaid plans (Bruen, 2002) . Bruen used CMS-64 data, net of rebates from drug manufacturers, for 50 States, Washington, DC, and other jurisdictions. He also reported that drug spending represented about 10 percent of total Medicaid spending and 14 percent of total national spending on outpatient drugs. Also, most States experienced greater than 50 percent growth in prescription drug spending from 1997-2000. In a recent survey, 36 States identified prescription drugs as the top Medicaid cost driver in 2001 (Smith and Ellis, 2001) . Even though Medicaid coverage of outpatient prescription drugs is optional, all States provide prescription drug coverage for categorically needy beneficiaries. An additional 35 States provide some coverage of prescription drugs for medically needy beneficiaries.
In 2000, Medicaid provided health insurance to more than 44 million beneficiaries-16 percent of the U.S. population; $195.5 billion in Medicaid payments-15 percent of total national health care spending; and nearly $21 billion in Medicaid drug payments-17 percent of total national health care spending for drugs (Levit, 2003 ; U.S. Bureau of the Census, 2003; Klemm, 2003) .
Regarding fiscal constraint, the weak economy that has persisted since the September 11, 2001 attacks has created a severe budget crisis for most States (George Washington University, 2003) . Many States are considering major cuts to optional Medicaid eligibility and coverage provisions (Kaiser Commission on Medicaid and the Uninsured, 2002a; Toner and Pear, 2003; Desonia, 2002; and Holahan, Weiner, and Lutzky, 2002) . Also, most States are using mechanisms and/or limits to contain prescription drug cost increases (Bruen, 2002) . These features include copayment, prior authorization, generic substitution, fail-first provisions, multi-tiered formularies, preferred drug lists, and number of prescription limits.
In a previous article, we indicated that Medicaid prescription drug spending increases were a major factor in overall Medicaid spending increases from 1990-1997 (Baugh, Pine, and Blackwell, 1999) . This article provides an update to our previous findings by analyzing Medicaid prescription drug spending for the entire decade of the 1990s (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) . Because virtually all Medicaid aged enrollees and nearly one-half of Medicaid disabled enrollees are enrolled in Medicare, the analysis provides important information on Medicaid prescription drug spending for these groups. Additionally, our analysis includes initial data on Medicaid prescription drug spending when drugs are organized by therapeutic use. This latter approach allows us to begin the process of examining Medicaid utilization and payments based on prescription drug mix. Our findings provide additional information to policymakers as the debate over cost and finance continues.
METHODOLOGY
Five data sources were used for this article. Medicaid utilization and spending trends were taken from the HCFA-2082, the CMS-64, and Medicaid Statistical Information System (MSIS) tables (Centers for Medicare & Medicaid Services, 2003) . Data on national prescription drug spending were taken from the NHE statistics. Data from the MSIS and the State Medicaid Research Files (SMRFs) were used for analyses to: (1) assess the impact of Medicaid managed care enrollment on prescription drug utilization and payments, (2) analyze Medicaid prescription drug utilization and payments by selected beneficiary characteristics, and (3) present Medicaid prescription drug payments by therapeutic use.
HCFA-2082 and MSIS Tables
The HCFA-2082 form "Statistical Reports on Medical Care: Eligibles, Recipients, Payments and Services" is an annual statistical report, by Federal FY, that is based on State Medicaid data reporting to CMS during the years 1990-1998. Some States submitted summary data directly to CMS and others submitted MSIS person-level enrollment and claims data. For these States, CMS prepared the summar y statistics from MSIS data. Beginning in FY 1999, all States were required to submit MSIS data to CMS and HCFA-2082 reporting requirements ended. The Medicaid trend data for 1999 and 2000 were prepared from MSIS data.
CMS-64 Data
The CMS-64 is an accounting statement of actual expenditures made by the States for which they are entitled to receive Federal reimbursement under Title XIX. These CMS-64 statistics are Medicaid payment amounts prior to the collection of rebates from the drug manufacturers.
National Health Expenditures
Annually, CMS' Office of the Actuary estimates national health spending in the United States. The NHE estimates health spending by type of service (e.g., hospital care, physician services, nursing home care, and prescription drugs) according to the sources that pay for these services (e.g., Medicare, Medicaid, private health insurance, and out-of-pocket spending). Estimates are based on information collected from public organizations such as the U.S. Bureau of the Census, CMS, the U.S. Bureau of Labor Statistics, and other Federal and State government agencies that fund medical programs and from private organizations such as the American Hospital Association and the Health Insurance Association of America.
Prescription drug expenditures are limited to retail purchases of these products by consumers. They do not include prescription drugs purchased as part of a hospital stay or directly from a physician since these expenditures are included with either hospital or physician services. Prescription drug spending is based most recently on data from IMS Health, which collects data on pharmacy transactions in different retail outlets. Expenditure estimates for earlier years are based on information collected by the U.S. Bureau of the Census in the Census of Retail Trade services called Merchandise Line Sales. This survey collects data on the value of prescription drug sales from retail outlets such as drugstores and grocery stores (Levit, 1999) .
MSIS and SMRF Data
For FY 1998, MSIS data files for 35 States were available to develop estimates of prescription drug utilization and spending for dually eligible beneficiaries by selected characteristics: disabled eligibility, aged eligibility by age group, sex, and beneficiary residence. Data on prescription drug utilization and payments for these States were tabulated by therapeutic use using the latest available SMRF data for 1997 from 29 States.
Analytic Measures
Payments-This is total Medicaid payment for prescription drugs during the CY. Payments are gross dollar amounts prior to the receipt of rebates from drug manufacturers. These Medicaid payments represent all prescription drugs provided under FFS (i.e., prescription drugs for which Medicaid paid a pharmacy claim).
Recipients-This is a count of the number of unique Medicaid beneficiaries who received at least one covered drug during the year. Even if a Medicaid beneficiary was covered under a prepaid plan during the year, and the person received at least one FFS drug, the beneficiary is counted as a drug recipient.
Prescriptions-This is the total number of filled prescriptions, original and refills, for Medicaid beneficiaries during the CY.
Rate Measures-The basic statistics, defined earlier, were used to create two rate measures for drugs: payment per prescription, and payment per recipient.
Eligibility Group-This is the program authority whereby a person receives Medicaid eligibility, known as Medicaid "basis of eligibility" (e.g., aged, blind/ disabled, children, and adults).
Age-Attained age as of December 31 of the year is aggregated into 5-year age groups for the aged, as follows: 65-69, 70-74, 75-79, 80-84 and 85 or over.
Sex-Statistics are reported for males and females. Data are omitted for persons for whom sex was unknown.
Beneficiary Residence-The county of residence for each beneficiary was identified as either a metropolitan or non-metropolitan county.
Therapeutic Category of Drugs-Drugs have been categorized by therapeutic category using Medi-Span (Wolters Kluwer Health, 2003) .
Data Limitations
These Medicaid data do not capture all drugs provided to Medicaid enrollees. Several factors may result in undercounts of numbers of prescriptions and payments.
Encounter records for prescription drugs provided by prepaid plans are omitted from this analysis because reporting of encounter records is currently incomplete and unreliable. Therefore, data on utilization and payments for prescription drugs are missing for services covered by a prepaid plan. The omission of these data is mitigated, in part, because many beneficiaries who are enrolled in prepaid plans receive some or all of their drugs under FFS systems. The impact of this limitation is discussed later.
The analysis omits prescription drugs provided to Medicaid enrollees during hospital stays and, for a small number of States, during nursing home stays. It also omits over-the-counter drugs provided during nursing home stays for most States. In these instances, drugs are included in the facility reimbursement rate and are not separately identifiable.
Medicaid data do not include out-of-pocket payments that Medicaid enrollees may make for their prescription drugs or thirdparty payments made by other insurers.
Another factor that affects analysis of these data is program variation across the States. Program choices include optional eligibility groups, coverage of selected prescription drugs, restrictions on prescription drug use, and payment methods. Also, States vary greatly in terms of implementing managed care, including full or partially capitated plans under either section 1915(b) or section 1115 provisions. The effects of these variations are not fully measurable.
External factors may also affect study findings. For example, analyses do not account for major Medicaid policy changes such as welfare reform, economic variables that affect an individual's decision to apply for Medicaid enrollment, and changes in the practice of medicine.
FINDINGS Prescription Drug Payment Trends
Total Medicaid payments for outpatient prescription drugs grew from $4.4 billion in 1990 to greater than $20 billion in 2000, an average annual increase of 16.3 percent (Figure 1 ). Large yearly increases were observed in 1991 (22.7 percent) and 1992 (24.7 percent), when the prescription drug rebate program was being implemented (Figure 2 ). After 1992, annual increases steadily declined through 1996. After 1996, annual increases grew steadily to 20.8 percent by 2000. Data from the CMS-64 confirm that prescription drug spending continued to increase at a high rate in 2001 and 2002 (20.0 and 18.9 percent, respectively) .
Throughout the decade, disabled persons accounted for the highest Medicaid drug payment amount compared with the other eligibility groups (Figure 1 ). Drug payments for disabled persons experienced the highest growth over the decade at an average annual rate of 20.1 percent.
By 2000, drug spending for the disabled ($11.6 billion) was more than double the amount for the aged ($5.4 billion). In addition, the proportion of total drug spending for the disabled increased from 42 percent in 1990 to 58 percent in 2000.
During the 1990s, Medicaid drug payments for the aged increased from $1.5 billion to $5.4 billion, an annual average increase of 13.5 percent. Together, the aged and disabled represented 85 percent of total Medicaid prescription drug spending in 2000. While Medicaid prescription drug spending levels were much lower for children ($1.6 billion) and adults ($1.4 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 5,000
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1 Medicaid prescription drug payments are gross amounts prior to the receipt of rebates to the States by prescription drug manufacturers. Medicaid prescription drug payments include all payments for prescription drugs provided under an FFS setting (i.e., prescription drugs for which Medicaid paid a pharmacy claim). Since Medicaid pays a single premium to a prepaid plan for all covered services, it is not possible to identify prescription drug payment when they are covered by a prepaid plan. To this extent, Medicaid prescription drug payments, presented here, may understate total Medicaid payments for prescription drugs. Data are reported for the 50 States and the District of Columbia and exclude other Medicaid jurisdictions. Although Hawaii did not report for 2000, their 1999 data were used as an estimate for 2000.
2 The Medicaid eligibility group identifies the basis on which Medicaid eligibility was determined, regardless of cash assistance status. The blind/disabled group includes individuals of any age who were determined to be eligible because of disability. The children's group includes foster care children. The all group includes a small number of individuals that are not reported in the other four groups.
billion) in 2000, spending for these two groups also increased in the 1990s. The average annual rate of increased Medicaid drug spending during the decade was 13.4 percent for children and 9.7 percent for adults. Between 1999-2000, drug payments increased sharply for each of the eligibility groups: aged (17.5 percent), disabled (23.0 percent), children (19.4 percent), and adults (21.5 percent). Figure 3 shows Medicaid prescription drug payments as a percent of total Medicaid payments during the decade. For all beneficiaries, prescription drug payments increased from 6.8 percent (1990) to 11.9 percent (2000) of total payments. Similarly, drug payments increased from 7.0 to 12.0 percent of total payments for the aged over these years. Drug payments for the disabled rose from 7.6 percent (1990) to 15.9 percent (2000) of total payments. The increase for adults was less dramatic. In 1990, drug payments represented 6.7 percent of total Medicaid spending for adults and, by 2000, drug payments rose to 8.1 percent of total payments for adults. From 1990 to 1996, prescription drugs were a steadily increasing percent of total Medicaid spending for children. However, there were intermittent increases and decreases after 1996. This finding may reflect the fact that many Medicaid children were being enrolled in prepaid plans in the late 1990s. 
Prescription Drug Recipient Trends
From 1990 to 1994, the number of Medicaid prescription drug recipients increased steadily from 17.3 to 24.4 million (Figure 4) . Then, the number decreased to 19.6 million by 1998. After 1998, the numbers began to increase again, reaching 20.5 million in 2000. Recipient trends for aged, adult, and child beneficiaries followed this same pattern during the 1990s. 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 However, the numbers of disabled prescription drug recipients grew more consistently during the decade, with only small declines in 1997 and 1998. As a result, the disabled increased from 17.5 percent (1990) to 24.4 percent (2000) of total drug recipients. Each of the other three groups represented a smaller percent of total drug recipients in 2000 than they did in 1990. Overall, the number of Medicaid drug recipients increased by an annual average of 1.7 percent per year. This statistic ranged from a high of just over 5 percent for the disabled to a 0.2-percent decline for adults. Recipient trends could be affected by many factors, such as health of the economy and enrollment in prepaid plans. Medicaid prescription drug recipients, by State, are presented in Table 2 for 2000. The largest number of prescription drug recipients nationally was children (8.3 million), greater than the number of disabled (5.0 million), more than double the number of adults (4.0 million), and nearly three times the number of aged (2.9 million). California had fewer children as drug recipients than adults. Both Texas and New York had larger numbers of children who received prescription drugs than California. 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 1 A Medicaid prescription drug recipient is a Medicaid enrollee who received at least one covered prescription drug during the FY. If an enrollee was covered under a prepaid plan, providing either partial or comprehensive coverage during the year, and had at least one FFS claim for a prescription drug during the FY, that enrollee is counted both as a recipient and a prescription drug recipient. Otherwise, enrollees covered under prepaid plans are excluded from recipient counts because it is not possible to identify the plan enrollees who received Medicaid covered services. Therefore, these data may understate the number of recipients and prescription drug recipients. Data are reported for the 50 States and the District of Columbia and exclude other Medicaid jurisdictions. Although Hawaii did not report for 2000, their 1999 data were used as an estimate for 2000.
HEALTH CARE FINANCING REVIEW/Spring 2004/Volume
2 The Medicaid eligibility group identifies the basis on which Medicaid eligibility was determined, regardless of cash assistance status. The blind/disabled group includes individuals of any age who were determined to be eligible because of disability. The children's group includes foster care children. The all group includes a small number of individuals that are not reported in the other four groups. This finding could be a result of enrollment of children in prepaid plans in California. In addition, this finding is largely responsible for the observed decline in national totals between 1997-2000. Otherwise, California had the largest number of aged, disabled, and adult prescription drug recipients. Figure 5 compares the percent of total Medicaid prescription drug recipients with the percent of total Medicaid prescription drug payments for each eligibility group in 2000. Together, children and adults were 60.8 percent of total prescription drug recipients, but they accounted for only 15.0 percent of prescription drug payments. In contrast, the disabled were less than 25 percent of total prescription drug recipients, but they accounted for over 58 percent of prescription drug payments. Similarly, the aged were 14 percent of total 2 Medicaid prescription drug payments are gross amounts prior to the receipt of rebates to the States by prescription drug manufacturers. Medicaid prescription drug payments include all payments for prescription drugs provided under an FFS setting (i.e., prescription drugs for which Medicaid paid a pharmacy claim). Since Medicaid pays a single premium to a prepaid plan for all covered services, it is not possible to identify prescription drug payment when they are covered by a prepaid plan. To this extent, Medicaid prescription drug payments presented here may understate total Medicaid payments for prescription drugs.
3 The Medicaid eligibility group identifies the basis on which Medicaid eligibility was determined, regardless of cash assistance status. The blind/disabled group includes individuals of any age who were determined to be eligible because of disability. The children's group includes foster care children. A small number of individuals that are not reported in these four groups have been excluded. prescription drug recipients and represented nearly 27 percent of total prescription drug payments. In comparison to the data we presented for 1997, the percent of total drug recipients and payments for the disabled has increased between 1997-2000. Aged and disabled beneficiaries have higher utilization of inpatient hospital and nursing facility services than adults and children. If it were possible to separate the cost of these drugs from other institutional services, the differences observed would be even larger.
Prescription Drug Payment Per Recipient Trends
Between 1990-2000, prescription drug payment per recipient grew from $256 to $975 (data not shown), an annual average increase of 14.3 percent. This increase in the payment rate is lower than the 16.3 percent average annual increase in total Medicaid payments during the decade. This is because there was a small average annual increase of 1.7 percent in the number of drug recipients over this time period.
The overall payment per recipient masked wide variations across eligibility groups. Spending per recipient for prescription drugs was higher throughout the decade for the disabled than for the other eligibility groups. In 1990, payment per recipient was only 6 percent higher for the disabled ($617) than for the aged ($582). By 2000, the difference was nearly 25 percent ($2,314 for the disabled versus $1,853 for the aged). In 1990, payment per recipient for the disabled was 10 times the amount for children ($617 for the disabled versus $61 for children). By 2000, spending for the disabled was 12 times the amount for children ($2,314 for the disabled versus $188 for children). Similarly, spending for the disabled increased from 4.4 times the amount for adults in 1990 to 5.8 times the amount for adults in 2000.
The same general patterns in payment per recipient by eligibility group that were observed in the national data for 2000 also persisted in data for individual States (Table  3) . However, there were variations across States. Payment per aged recipient ranged from $1,414 in Minnesota to $2,695 in Indiana. For the disabled, the variation was greater, ranging from $1,469 in Michigan to $3,314 in Connecticut. Because payment per recipient was much lower for children and adults, the variation across States in payment for these groups was much smaller. State differences can be attributed to many factors, including enrollment in prepaid plans and controls on drug utilization.
In order to gain a better understanding of Medicaid drug spending increases presented here, it is important to develop a knowledge of Medicaid drug spending: (1) variations by selected beneficiary characteristics, (2) levels by therapeutic usage, and (3) in comparison to spending increases for drugs by other payers (e.g., public, private, and beneficiaries out-of-pocket). The next three sections are an introduction to these issues.
Differences for Dually Eligible Persons
Because of the ongoing interest in the cost of drugs for Medicare beneficiaries, analysis of FY 1998 data for dually eligible beneficiaries was performed. Medicaid prescription drug payments per recipient are presented by selected demographic characteristics for dually aged and disabled beneficiaries ( Figure 6 ). There was no substantial variation in payment amounts among aged beneficiaries, by sex and age group, except that there was a slight decline in payments for persons age 85 or over. Similarly, payment per recipient for dually disabled beneficiaries residing in non-metropolitan areas was comparable to that of aged beneficiaries. However, payment per recipient for both male and female disabled beneficiaries in metropolitan areas was much higher than for that of the other groups.
Differences by Drug Therapeutic Categor y
Because States are faced with the challenge of managing drug expenditures under extreme budget pressure, there is a need to examine variations more closely by therapeutic use. inhibitors) at $982 million (14.7 percent). Cardiovascular agents were followed by anti-infective agents at $835 million (12.5 percent) and gastrointestinal agents at $785 million (11.8 percent) . A large proportion of total drug spending (over 56 percent) was concentrated in these four categories. The five categories with the lowest spending levels (miscellaneous psychotherapeutic and neurological agents, stimulants/anti-obesity/anorexiants, genitourinary products, antineoplastic agents, and biologicals) accounted for only 4 percent of total prescription drug spending. However, spending levels differed by eligibility group. The highest spending level for disabled beneficiaries was for CNS drugs. For the aged, cardiovascular agents accounted for the highest amount. For children and adults, the highest spending level was for anti-infective agents (data not shown). There were nearly 197 million prescriptions filled in these States in 1997. The largest number of prescriptions was filled for cardiovascular agents (over 33 million or 17 percent of the total). There were also large numbers of prescriptions filled for CNS drugs, analgesics and anesthetics, antiinfective agents, and respiratory agents. Drugs from these five categories were 63 percent of all filled prescriptions. Five categories (miscellaneous products, miscellaneous psychotherapeutic and neurological agents, stimulants/anti-obesity/anorexiants, antineoplastic agents, and biologicals) had small numbers of filled prescriptions, delivered by prepaid plans is much less serious than suggested by other sources (Health Care Financing Administration, 1998) . Medicaid in the NHE data (15.2 percent). Medicaid increases were comparable to those experienced by other public payers, but lower than the increase for private payers (over 19 percent) and much higher than out-of-pocket increases (about 5 percent).
SUMMARY OF FINDINGS

DISCUSSION
Spending increases for prescription drugs present a continued challenge to those who shape program policy (Kaiser Commission on Medicaid and the Uninsured, 2002b). The problem is exacerbated by severity of the current budget crisis in many States. The choices are difficultincreased taxation, cuts in other State programs, and cuts in Medicaid (Smith, 2002) . States will continue to implement drug utilization controls to gain some savings, but associated savings may not be enough.
The significance of effective drug therapy management assumes an even greater importance as concerns for cost-efficiency continue. Data-driven approaches, such as the use of MSIS data, can assist in effective decisionmaking by monitoring patterns of drug utilization and payments. These data could be combined with clinical analysis of patient outcomes under alternative drug regimens to identify cost effective therapies. Such analyses can help eliminate over utilization and reduce the cost of alternate care resulting from under utilization.
Second, Congress has enacted a Medicare prescription drug benefit. Our results also indicate that spending for prescription drugs for aged and disabled Medicaid enrollees has increased dramatically in the last decade. Unless the trend changes, spending under the Medicare benefit will probably continue to grow rapidly. The Medicaid data provide a base for understanding current prescription drug costs and estimating future spending for both Medicaid and Medicare. Enhanced coding in the data for 1999 and later years will permit analysis of drug spending for various types of dually eligible enrollees (e.g., qualified medicare beneficiaries, qualified disabled working individuals, and other buyin individuals). Since a Medicare benefit has been enacted, another valuable analytic tool would be a Medicare prescription drug database.
Given the severity of the State budget crisis and ongoing concerns about cost containment by other public and private payers, it is unlikely that these payers will allow growth to continue at these rates. That probably means that beneficiaries may incur greater increases in out-of-pocket payments. This is a particular concern for poor and other low-income groups who can least afford out-of-pocket payment for needed prescription drugs. A better understanding of the factors driving spending increases and variations is needed. As illustrated by the analysis of therapeutic categories, we will expand our knowledge of these factors greatly by analyzing drug spending in the four most expensive categories.
We have avoided undue speculation as to the effects of various factors on observed spending increases. The increases are a result of many factors (and possibly interactions among the factors), including: increasing enrollment (particularly for disabled persons), increased use of drugs, cost inflation, new drug therapies (e.g., blockbuster drugs), the use of single source versus generic drugs and State policies to control drug utilization. A number of factors have been identified here, but the impact and possible interaction of these and other factors should receive appropriate treatment in future research.
